vocimagene amiretrorepvec
AXP000126.1 · Oncolytic virus
- Platform
- replicating gammaretroviral vector (amphotropic MLV-based)
- Originator
- Tocagen
- Sponsor
- Tocagen
Names
Virus
- Role
- Oncolytic
- Family
- Retroviridae
- Virus
- murine leukemia virus (NCBI Taxonomy 11786)
- Strain
- amphotropic MLV-based replicating vector
- Replication
- replicating
- Modifications
- replication-competent retroviral vector carrying an optimised yeast cytosine deaminase cassette
- Transgenes
- yeast cytosine deaminase (CD)
- Route
- intracerebral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C91734
- FDA UNII
- DC4WO3WA4Q
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Recruiting | Phase 1/2 | 2025-01-08 | 2028-01-31 | 70 | High Grade Glioma; MGMT-Methylated Glioblastoma; MGMT-Unmethylated Glioblastoma |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | Withdrawn | Phase 2/3 | 2020-01-31 | 2025-11-30 | 0 | Anaplastic Astrocytoma; Glioblastoma; Oligodendroglioma; Supratentorial Glioblastoma |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | Withdrawn | Phase 1 | 2019-12 | 2022-01 | 0 | Bladder Cancer |
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care | Withdrawn | Phase 1 | 2017-01 | 2022-11 | 0 | Newly Diagnosed High Grade Glioma (HGG) |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | Terminated | Phase 1 | 2016-07 | 2019-05 | 21 | Bladder Cancer; Colorectal Cancer; Head and Neck Cancer; IDH1 Mutated Solid Tumors; IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting); Lymphoma; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Sarcoma; Triple Negative Breast Cancer |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma | Terminated | Phase 2/3 | 2015-11-30 | 2019-05-31 | 403 | Anaplastic Astrocytoma; Glioblastoma Multiforme |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | Completed | Phase 1 | 2014-02 | 2016-03-03 | 17 | Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma Multiforme |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | Completed | Phase 1 | 2012-02 | 2016-04-12 | 58 | Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma Multiforme |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | Terminated | Phase 1 | 2011-02 | 2019-12 | 65 | Astrocytoma; Glioblastoma Multiforme; Gliomas, Malignant |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | Completed | Phase 1 | 2010-07 | 2016-08-18 | 54 | Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40842153 | A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in title: vocimagene amiretrorepvec |
| PMID 32816892 | Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | name in title: vocimagene amiretrorepvec |
| PMID 33119048 | Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. | JAMA oncology | 2020 | cited by trial NCT02414165 |
| PMID 29322091 | A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. | Molecular therapy oncolytics | 2018 | cited by trial NCT02576665 |
| PMID 29735994 | Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. | Cancer gene therapy | 2018 | cited by trial NCT02576665 |
| PMID 29762717 | Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. | Neuro-oncology | 2018 | cited by trial NCT01470794 |
| PMID 29945998 | Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2018 | name in title: Toca 511 |
| PMID 27252174 | Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. | Science translational medicine | 2016 | cited by trial NCT02414165 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39039195 | Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. | Cancer gene therapy | 2024 | name in abstract: Toca 511 |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: Toca 511 |
| PMID 36497300 | Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. | Cancers | 2022 | name in title: vocimagene amiretrorepvec |
| PMID 33724117 | Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. | Expert opinion on biological therapy | 2021 | name in title: Toca 511 |
| PMID 34321837 | Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials. | Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2021 | name in abstract: vocimagene amiretrorepvec |
| PMID 30676111 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. | Expert opinion on investigational drugs | 2019 | name in title: Toca 511 |
| PMID 29117980 | Treating Recurrent Glioma with Toca 511. | Cancer discovery | 2018 | name in title: Toca 511 |
| PMID 29216761 | Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models. | Human gene therapy | 2018 | name in abstract: Toca 511 |
| PMID 30563098 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? | Cancers | 2018 | name in abstract: Toca 511 |
| PMID 28387831 | Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. | Neuro-oncology | 2017 | name in abstract: Toca 511 |
| PMID 28387849 | Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. | Neuro-oncology | 2017 | name in title: Toca 511 |
| PMID 26467507 | Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. | Human gene therapy methods | 2016 | name in abstract: Toca 511 |
| PMID 27166379 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. | Neuro-oncology | 2016 | name in title: Toca 511 |
| PMID 27861411 | "Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma. | Neurosurgery | 2016 | name in title: Toca 511 |
| PMID 25419577 | Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. | Human gene therapy | 2015 | name in title: Toca 511 |
| PMID 24941977 | Immunotherapy for high-grade glioma. | Future oncology (London, England) | 2014 | name in abstract: Toca 511 |
| PMID 24965455 | Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity. | Journal of virology | 2014 | name in abstract: Toca 511 |
| PMID 25301172 | Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. | Cancer gene therapy | 2014 | name in abstract: Toca 511 |
| PMID 26015967 | Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. | Molecular therapy. Methods & clinical development | 2014 | name in abstract: Toca 511 |
| PMID 23969884 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. | Cancer gene therapy | 2013 | name in title: Toca 511 |
| PMID 28160846 | Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression. | Molecular therapy : the journal of the American Society of Gene Therapy | 2013 | name in title: Toca 511 |
| PMID 22070930 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. | Neuro-oncology | 2012 | name in abstract: Toca 511 |
| PMID 22547150 | Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in title: Toca 511 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21CA282543 | A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE | SHAH, ASHISH HARISH | 2023–2024 | name in abstract: vocimagene amiretrorepvec |
| R01CA213119 | Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | KASAHARA, NORIYUKI | 2017–2022 | name in abstract: Toca 511 |
| R33NS104454 | GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | KASAHARA, NORIYUKI | 2021–2021 | name in abstract: Toca 511 |
| R21NS104454 | GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | KASAHARA, NORIYUKI | 2019–2020 | name in abstract: Toca 511 |
| R01FD005732 | Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recurrent GBM-AA IND 14173 9Jul2015 | TOCAGEN, INC. | VISONNEAU, SOPHIE | 2017–2019 | name in title: Toca 511 |
| R43CA174090 | Retroviral replicating vector for prodrug activator gene therapy | TOCAGEN, INC. | JOLLY, DOUGLAS J. | 2012–2012 | name in abstract: vocimagene amiretrorepvec |
Notes
Replication-competent retroviral vector (Toca 511) delivering optimised yeast cytosine deaminase, which converts the companion prodrug 5-fluorocytosine (Toca FC, extended-release flucytosine) to 5-FU. Toca FC is a small molecule and not a separate virus program. Phase 3 Toca 5 missed its overall survival endpoint in September 2019; Tocagen merged into Forte Biosciences in 2020 and the programme ended.
How to cite
vocimagene amiretrorepvec (AXP000126.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000126.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.